Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AZASITE vs TYLENOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Azasite (azithromycin ophthalmic solution) is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis.
Acetaminophen is a centrally acting analgesic and antipyretic. Its mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, preferentially COX-2, and modulation of descending serotonergic pathways.
Treatment of bacterial conjunctivitis caused by susceptible organisms
Mild to moderate pain (FDA-approved),Fever (FDA-approved),Osteoarthritis pain (off-label),Patent ductus arteriosus in neonates (off-label IV formulation)
1 drop of 1% ophthalmic solution to each affected eye twice daily (approximately 12 hours apart) for 2 days, then once daily for 5 days.
650 mg orally every 4-6 hours or 1000 mg orally every 6 hours; maximum 4000 mg per day.
Terminal elimination half-life: 68-72 hours; facilitates once-weekly dosing for trachoma.
Terminal elimination half-life is 2-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment
Not significantly metabolized; primarily excreted unchanged in bile and urine.
Primarily hepatic via conjugation with glucuronide (UGT1A1, UGT1A6, UGT1A9) and sulfate (SULT1A1, SULT1A3); minor oxidation by CYP2E1, CYP1A2, and CYP3A4 to N-acetyl-p-benzoquinone imine (NAPQI), which is detoxified by glutathione.
Primarily hepatic/biliary (fecal) as unchanged drug: ~70% fecal, ~20% renal (mostly unchanged), ~0.5% urinary as metabolites.
Renal excretion of conjugated metabolites (glucuronide and sulfate conjugates) accounts for >90% of elimination; less than 5% excreted unchanged; minor biliary/fecal elimination (<5%)
~50-60% bound to plasma proteins (primarily albumin).
10-25% bound to plasma proteins (primarily albumin); binding is minimal and not clinically significant
Vd: ~100 L/kg (extensive tissue penetration; not meaningful for topical use; systemic Vd based on IV data).
0.8-1.0 L/kg; low Vd indicates limited extravascular distribution, consistent with limited CNS penetration
Ophthalmic: negligible systemic absorption (<10% of topical dose) due to low corneal permeability and dilution by tears.
Oral: 60-90% (first-pass hepatic metabolism reduces bioavailability); Rectal: 70-90%; Intravenous: 100%
No dosage adjustment required for ophthalmic use.
GFR 10-50 m L/min: Administer every 6 hours. GFR <10 m L/min: Administer every 8 hours.
No dosage adjustment required for ophthalmic use.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%; maximum 2000 mg/day. Child-Pugh C: Reduce dose by 75%; maximum 1000 mg/day.
Safety and efficacy in pediatric patients have not been established; limited data available.
10-15 mg/kg orally every 4-6 hours; maximum 75 mg/kg/day or 5 doses per day.
No specific dosage adjustment recommended; use same dosing as for adults.
Reduce dose by 25-50% in frail elderly; maximum 3000 mg/day due to increased hepatotoxicity risk.
None
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen in doses exceeding 4000 mg per day. The risk of acute liver failure may be higher in individuals with underlying liver disease and in those who consume alcohol chronically.
Prolonged use may result in overgrowth of nonsusceptible organisms,Contact lens should not be worn during treatment,Do not inject subconjunctivally or introduce into the anterior chamber
Hepatotoxicity: Risk increases with doses > 4000 mg/day, chronic alcohol use, or preexisting liver disease.,Severe skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis.,Hypersensitivity: Rare anaphylaxis.
Hypersensitivity to azithromycin, erythromycin, or any macrolide antibiotic,Hypersensitivity to any component of the formulation
Hypersensitivity to acetaminophen,Severe hepatic impairment (e.g., active liver disease)
No clinically significant food interactions. Administer with or without food as per dosing instructions.
No significant food interactions. Alcohol consumption increases risk of hepatotoxicity; avoid concurrent use. High-carbohydrate meals may slightly delay absorption.
Azasite (azithromycin ophthalmic) is classified as FDA Pregnancy Category B. Systemic absorption is minimal after ophthalmic administration. No teratogenic effects have been observed in animal studies at doses up to 200 mg/kg/day (systemic). Limited human data; risk is considered low. First trimester: unlikely to cause major malformations. Second and third trimesters: no specific risks identified.
Acetaminophen crosses the placenta. First trimester: no increased risk of major malformations in prospective studies; retrospective studies show possible association with gastroschisis and neural tube defects but confounding by indication is likely. Second and third trimesters: no consistent evidence of adverse fetal effects; chronic high doses may cause maternal hepatotoxicity with secondary fetal effects. Avoid prolonged high-dose therapy.
Azithromycin is excreted into human milk after systemic administration; the M/P ratio is approximately 0.90. After ophthalmic administration, systemic absorption is minimal, resulting in negligible exposure to the infant. Considered compatible with breastfeeding; use with caution if eye drops are applied multiple times daily.
Acetaminophen is excreted into breast milk in low amounts (M/P ratio approximately 0.9; peak milk concentration 10-15 µg/m L after 1g oral dose). Relative infant dose is <2% of maternal weight-adjusted dose. Considered compatible with breastfeeding; monitor infant for rash or drowsiness.
No dose adjustment is necessary for ophthalmic use in pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered clearance) do not significantly affect topical ocular drug levels due to negligible systemic absorption.
Increased clearance in pregnancy may reduce AUC by 25-30%; recommend standard dosing (500-1000mg every 4-6 hours, max 3000-4000mg/day). No dosage adjustment typically needed. Avoid extended-release formulations due to variable absorption.
Azasite (azithromycin ophthalmic solution) is a macrolide antibiotic used for bacterial conjunctivitis. Shake well before each use. Avoid contact with contact lenses during treatment. Do not use for more than 14 days. Monitor for signs of hypersensitivity.
Acetaminophen has minimal anti-inflammatory effect; prefer NSAIDs for inflammation. Max daily dose 3 g (or 2 g in at-risk patients). N-acetylcysteine is antidote for overdose; administer if serum level above nomogram line. Avoid in severe hepatic impairment. Intravenous formulation available for acute pain. Onset of action 30-60 min, duration 4-6 h. No effect on platelets or GI mucosa.
Shake the bottle well before each use.,Wash hands before and after application.,Do not touch the dropper tip to any surface.,Remove contact lenses before use; do not reinsert during treatment.,Instill the prescribed number of drops in the affected eye(s).,Avoid wearing eye makeup during treatment.,Finish the entire course of medication even if symptoms improve.,Report any worsening, itching, or swelling to your doctor.
Do not exceed 3 g (3000 mg) per day from all products.,Check all over-the-counter medications for acetaminophen content.,Do not take with alcohol or if you have liver disease.,Seek immediate medical attention if overdose is suspected.,May be taken with food if GI upset occurs (though rare).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AZASITE vs TYLENOL, answered by our medical review team.
AZASITE is a Macrolide Antibiotic that works by Azasite (azithromycin ophthalmic solution) is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis.. TYLENOL is a Analgesic (non-opioid) that works by Acetaminophen is a centrally acting analgesic and antipyretic. Its mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, preferentially COX-2, and modulation of descending serotonergic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AZASITE and TYLENOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AZASITE is: 1 drop of 1% ophthalmic solution to each affected eye twice daily (approximately 12 hours apart) for 2 days, then once daily for 5 days.. The standard adult dose of TYLENOL is: 650 mg orally every 4-6 hours or 1000 mg orally every 6 hours; maximum 4000 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AZASITE and TYLENOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AZASITE is classified as Category C. Azasite (azithromycin ophthalmic) is classified as FDA Pregnancy Category B. Systemic absorption is minimal after ophthalmic administration. No teratogenic effects have been observ. TYLENOL is classified as Category C. Acetaminophen crosses the placenta. First trimester: no increased risk of major malformations in prospective studies; retrospective studies show possible association with gastrosch. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.